ArticleJundishapur journal of microbiology2015
In Silico Investigation for Evaluation of the Potential of the SclA Protein in Streptococcus pyogenes.
Article in Jundishapur journal of microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptococcus pyogenes is an important pathogen that is associated with a range of infections in humans, and causes common and severe invasive diseases. Currently, antimicrobial therapy is the first choice for the treatment of S. pyogenes; however, the emergence of antimicrobial resistance and side effects of antibacterial drugs is increasing. Consequently, there is an increased demand for novel drug targets and vaccine design.
objectivesTo develop an effective vaccine against Streptococcus pyogenes (group A streptococcus) , we described a novel collagen-like surface protein of S. pyogenes which is important virulence factors. MATERIALS AND
methodsIn this study, we focused on the SclA protein of S. pyogenes and characterized it using bioinformatic tools to introduce it as a candidate novel drug as a candidate for use in vaccine design. The secondary structure was determined and the 3D structure was modeled using SWISS-MODEL workspace. The immune epitope database analysis (IEDB) resource was used to predict regions of SclA that are likely to be recognized as epitopes.
resultsThe SclA protein is present on the cell surface of the cell and has interact with a common ligand by its hypervariable NH2-terminal regions. The IEDB showed that the maximum peptide length that is likely to be predicted as an epitope is of 6 amino acids, from amino acid 26 to 31, with a score of 4.791. This epitope can be considered for use in Antibody and drug design.
conclusionsData from this study about SclA were not sufficient and further studies are needed; however, the information here suggests that SclA could be a candidate for further research on the design of drugs and vaccines against S. pyogenes infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.